Dyne Therapeutics (NASDAQ:DYN) Announces Quarterly Earnings Results

Dyne Therapeutics (NASDAQ:DYN) released its quarterly earnings data on Thursday. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.15), FiscalAI reports. During the same quarter last year, the firm earned ($0.76) EPS.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock traded up $0.71 during midday trading on Friday, reaching $18.07. The company had a trading volume of 2,359,185 shares, compared to its average volume of 2,812,952. The company has a market capitalization of $3.37 billion, a P/E ratio of -4.98 and a beta of 1.22. Dyne Therapeutics has a 12-month low of $14.00 and a 12-month high of $27.31. The firm’s fifty day simple moving average is $17.70 and its 200-day simple moving average is $19.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
• Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
• Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares in the company, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian Posner bought 2,500 shares of Dyne Therapeutics stock in a transaction on Friday, October 2nd. The shares were purchased at an average cost of $16.00 per share, with a total value of $40,000.00. Following the acquisition, the director directly owned 27,000 shares of the company’s stock, valued at approximately $432,000. The trade was a 10.20% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have sold 2,598,706 shares of company stock valued at $65,432,671. 9.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus set a $37.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Robert W. Baird decreased their price objective on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, September 9th. JPMorgan Chase & Co. lowered Dyne Therapeutics from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $17.00 to $10.00 in a report on Wednesday, September 9th. Cantor Fitzgerald reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.29.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.